S9 Ep23: Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
OncLive® On Air
00:00
Patient Selection and Dosing Considerations for Bispecific Antibodies in Multiple Myeloma
Exploring dosing and patient selection with taklister map and Eliranetamab, emphasizing monitoring and dosage adjustments. Bispecific antibodies are discussed as a rapid treatment option compared to CAR-T cell therapy.
Play episode from 08:40
Transcript
